Chronic Hepatitis
Chronic Hepatitis
Chronic Hepatitis
Author manuscript
J Perinatol. Author manuscript; available in PMC 2016 March 03.
Author Manuscript
3Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City,
IA, USA
Abstract
Our objective was to provide a comprehensive review of the current knowledge regarding
pregnancy and hepatitis B virus (HBV) or hepatitis C virus (HCV) infection as well as recent
efforts to reduce the rate of mother-to-child transmission (MTCT). Maternal infection with either
HBV or HCV has been linked to adverse pregnancy and birth outcomes, including MTCT. MTCT
for HBV has been reduced to approximately 5% overall in countries including the US that have
instituted postpartum neonatal HBV vaccination and immunoprophylaxis with hepatitis B immune
globulin. However, the rate of transmission of HBV to newborns is nearly 30% when maternal
HBV levels are greater than 200 000 IU ml1 (>6 log10 copies ml1). For these patients, new
Author Manuscript
guidelines from the European Association for the Study of the Liver (EASL) and the Asian Pacific
Association for the Study of the Liver (APASL) indicate that, in addition to neonatal vaccination
and immunoprophylaxis, treating with antiviral agents such as tenofovir disoproxil fumarate or
telbivudine during pregnancy beginning at 32 weeks of gestation is safe and effective in
preventing MTCT. In contrast to HBV, no therapeutic agents are yet available or recommended to
further decrease the risk of MTCT of HCV, which remains 3 to 10%. HCV MTCT can be
minimized by avoiding fetal scalp electrodes and birth trauma whenever possible. Young women
with HCV should be referred for treatment post delivery, and neonates should be closely followed
to rule out infection. New, better-tolerated treatment regimens for HCV are now available, which
should improve outcomes for all infected individuals.
INTRODUCTION
Author Manuscript
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are acquired by contaminated blood
product exposure, sexual activity or perinatal transmission. Although the prevalence of HBV
is relatively low in the US (0.4%), with approximately one million Americans chronically
infected by HBV,1 it is more prevalent in East Asia (8%)2 (China 2 to 18%, Taiwan 2 to
Correspondence: Dr KK Leslie, Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins
Dr, 31140-A PFP, Iowa City, IA 52242, USA. [email protected].
CONFLICT OF INTEREST
Kimberly K. Leslie and Kristina W. Thiel are cofounders of Immortagen, L.L.C. The authors declare no conflict of interest.
Dunkelberg et al. Page 2
19% and Hong Kong 4 to 10%, depending on the region),3 Southeast Asia (>6%)2
Author Manuscript
(Indonesia 2 to 9%, Thailand 1 to 25% and India 1 to 66%, depending on the region)3 and
sub-Saharan Africa (8 to 12%).2 Both Tropical Latin America and Central Latin America
have had a decrease in HBV prevalence since 1990 (to 1.6% in 2005).2 HCV is the most
common chronic blood-borne infection in the US, affecting nearly four million Americans.
Women of childbearing age have a 1 to 2% incidence of chronic HCV infection, with higher
rates in those with risk factors such as intravenous drug use.4 Pregnancy in patients with
chronic HBV or HCV is associated with mother-to-child transmission (MTCT) and may be
associated with increased maternal and fetal complications. In this review, we discuss the
relationship between HBV/HCV infection and adverse pregnancy outcomes. Also included
is a perspective on the current strategies to decrease the rate of MTCT. The published
literature was searched through MEDLINE and ClinicalTrials using search terms hepatitis
and pregnancy. The 107 studies cited represent the consensus regarding management of
Author Manuscript
Several large population studies indicate that there is increased risk for preterm birth (odds
ratio 1.4; 11.5% vs 7.9%, P<0.001), low birth weight (<2500 g) (odds ratio 1.39; 10.4% vs
7.8%, P = 0.009), premature rupture of membranes (8.9% vs 6.9%, P = 0.026), gestational
diabetes (13.2% vs 8.8%, P<0.02) and congenital abnormalities (odds ratio 1.55; 7.2% vs
5.1%, P = 0.01) in pregnancies associated with maternal HBV or HCV infection (Table
1).512 Maternal chronic HCV infection is also associated with cholestasis of
pregnancy,7,13,14 neonatal narcotic withdrawal syndrome7 and neonatal intensive care unit
admission.5,7,12
A confounding factor that limits interpretation of these studies is exposure to illicit drugs
during the prenatal period, especially heroin, methadone and amphetamines,5,7 which are
independently associated with low birth weight, preterm birth, congenital anomalies and
other adverse neonatal outcomes.7,15 Two of the largest studies showing adverse outcomes
Author Manuscript
associated with HBV or HCV included drug abuse, alcohol abuse and tobacco use in the
multivariate statistical analyses.5,7 Nonetheless, although pregnancies complicated by HBV
or HCV are clearly associated with adverse maternal and fetal outcomes, it is not as evident
if the etiology of these events are mediated by the viral infection, by other confounding
factors, or by a combination of factors.
HEPATITIS B IN PREGNANCY
Author Manuscript
In the US, the prevalence of chronic HBV infection in pregnancy is 0.2 to 6%, with rates
varying by race and ethnicity.10,16 In a study of pregnant women from four urban US areas,
Asian-American women had the highest prevalence of chronic HBV infection (6%),
followed by blacks (1%), whites (0.6%) and Hispanics (0.14%).16 Newborn infants
acquiring HBV infection by perinatal transmission have a greater than 95% chance of
becoming chronic HBV carriers.1719 Therefore, it is very important to institute maximally
effective measures to prevent MTCT.
have normal serum aspartate transaminase (AST) and alanine transaminase (ALT) levels,
but have very high HBV DNA levels (>10 million IU ml 1; >6 7 log10 copies ml1); they
typically are children, teenagers or young adults. Inactive HBV carriers are HBsAg-positive,
HBeAg-negative, hepatitis B e antibody positive, with undetectable or low (<1000 IU
ml 1;<6 3 log10 copies ml 1) HBV DNA levels and normal liver function tests. Patients
with chronic active HBV infection have increased AST and ALT levels, may be positive for
HBeAg and have HBV DNA levels over 20 000 IU ml1 (>5 log10 copies ml1).
infection (Asian, drug use, sexual exposure, incarceration, abnormal ALT) on admission for
delivery.
over 60% of pregnancies associated with acute HBV infection at or near term.24,25
post-partum reconstitution of the immune system. This post-partum HBV reactivation may
Author Manuscript
HBeAg-positive (indicative of active viral replication and infectivity), and almost all of
these infected infants became chronic HBsAg carriers.1719 Young women in the immune-
tolerant phase of chronic HBV infection are at high risk (up to 30%) for MTCT of HBV
infection, regardless of neonatal immunoprophylaxis with HBIG and HBV
vaccine.22,31,33,34,37,38 In contrast, chronic HBV infection occurred in fewer than 10% of
infants of HBeAg-negative mothers.39 Other risk factors for MTCT of HBV include
threatened preterm labor, prolonged labor and prior failure of immunoprophylaxis in
siblings.31
MTCT of HBV can occur at three stages of pregnancy: intrauterine, intra-partum or post-
partum. MTCT of HBV infection is thought to occur predominantly at or after birth based
on the high protective efficacy of immunoprophylaxis. Intrauterine MTCT of HBV is
reported to occur in 10 to 16% of pregnancies and probably accounts for the small
Author Manuscript
birthCurrent standard of care for the prevention of MTCT of HBV infection is treatment
of the newborn with HBIG and HBV vaccination (Table 3). At-risk neonates who received
HBV vaccine alone at birth had a 26 to 36% chance of MTCT of HBV infection,47 whereas
administration of HBIG alone at birth decreased the rate of perinatal HBV transmission to
15 to 20%.23 If HBIG and the HBV vaccine are administered to the neonate of an HBsAg-
positive mother within 12 h of delivery, approximately 5% of infants become chronic HBV
carriers, a reduction in MTCT of almost 90%.47,48 Overall, the use of HBIG and HBV
Author Manuscript
The Centers for Disease Control and Prevention (CDC) and the Advisory Committee on
Immunization Practices (ACIP) recommend administration of HBV vaccine and HBIG to at-
risk infants within 12 h of delivery, followed by completion of the hepatitis B vaccine series
within the first year of life.23 Newborns of mothers with unknown HBsAg status at the time
of birth should receive the HBV vaccine within 12 h of birth; if the mother is found to be
HBsAg-positive, the infant should receive HBIG as soon as possible (within 7 days of birth).
HBV is still transmitted from 8 to 30% of mothers with high levels of HBV DNA and
HBeAg positivity.31,33,37,38 For example, a recent Chinese study demonstrated a dose-
dependent correlation between maternal pre-delivery HBV DNA levels and rate of
immunoprophylaxis failure.35 All infants who failed immunoprophylaxis were born to
HBeAg-positive mothers with HBV DNA levels 6 log10 copies ml 1 ( 200 000 IU ml 1).
In a meta-analysis from the Netherlands, the only factor that significantly affected the
efficacy of immunoprophylaxis was the maternal HBV DNA level. There was 100%
efficacy with HBV DNA less than 150 pg ml 1 (~107 IU ml 1; 6 7 log10 copies ml 1),
but only 68% efficacy with HBV DNA levels greater than 150 pg ml1,22 which is
consistent with another report that found a 25 to 50% rate of MTCT of HBV infection with
maternal HBV DNA levels over 150 pg ml 1.51 Finally, in an Iranian study of infants who
received HBIG and HBV vaccine at birth, the rate of HBV infection was 1.5% in infants
Author Manuscript
born to women who were HBeAg-negative and 18% for infants born to women who were
HBeAg-positive.50 HBV DNA levels were not analyzed.
likelihood of MTCT of HBV infection and is safe for the mother and newborn. The most
recent meta-analysis included 15 randomized controlled trials with 1693 HBV carrier
mothers and demonstrated that lamivudine treatment beginning at week 28 of pregnancy
significantly decreased MTCT of HBV infection (relative risk 0.33 to 0.43); efficacy was
dependent on a decrease in maternal HBV DNA levels to less than 6 log10 copies ml 1 (200
000 IU ml1).56 A randomized controlled Chinese trial with lamivudine 100 mg per day in
HBeAg-positive mothers with HBV DNA greater than 6 log10 copies ml 1 in the third
(18 vs 39%).34 Starting lamivudine therapy at week 32 of pregnancy has been suggested to
achieve a sufficient reduction in HBV DNA level in case of an early delivery.31
TDF may also be the preferred antiviral for HBV infection in pregnancy given its potency,
safety profile and better resistance profile than lamivudine.58 TDF is a pregnancy category B
medication; it has been found to be safe in animal models, but with limited data in humans.
There are no prospective studies published for the use of TDF in pregnant women with HBV
mono-infection; however, it has been safely used in 1731 pregnant women with HIV (some
with HBV co-infection), and the rate of birth defects does not significantly differ from
pregnancies not exposed to TDF.31 Given that TDF, 300 mg daily, is a first-line treatment
for chronic active HBV infection, its use during the third trimester to prevent HBV
transmission is an appropriate option for mothers who need long-term treatment after
delivery,20,31 such as patients with chronic active HBV infection, AST or ALT levels
Author Manuscript
greater than 1.5 to 2 times normal, and an HBV DNA level over 20 000 IU ml 1 (5 log10
copies ml1).20
The safety of these antiviral agents is established by the Antiviral Pregnancy Registry,
Author Manuscript
which has tracked spontaneously reported maternal and fetal outcomes in women receiving
oral nucleoside drugs since 1989. As of 31 January 2008, 9889 pregnancies were reported
during which the mother had received an oral nucleoside analogue.60 The overall prevalence
of birth defects in infants exposed to any antiretroviral agent during the first trimester of 3.0
per 100 live births (117 of 3951), or in any trimester of 2.8 per 100 live births (261 of 9400),
was not significantly different from that reported in the general US population of 2.72 per
100 live births. Only infants exposed to the anti-HIV medication didanosine had a
significantly higher rate of birth defects than expected. The prevalence of birth defects with
Author Manuscript
lamivudine exposure in the first trimester (3.1%, 85 of 2784) and with TDF (2.2%, 11 of
491) were similar to population controls. The safety data for telbivudine in the Antiviral
Pregnancy Registry are limited.31
Because of limited data on secretion of antiviral agents into human breast milk, breast
feeding is not recommended by the makers of the nucleos(t)ide analogues if antiviral therapy
is continued after delivery. There are scanty data on secretion of TDF or its metabolite,
tenofovir, into animal or human breast milk. A single small human study found that small
amounts of tenofovir, but not TDF, are present in breast milk of HIV-1-infected women
taking TDF, representing 0.03% of the proposed oral HIV-prevention dose of tenofovir for
infants.61 Infant exposure to tenofovir through breastfeeding may be negligible because
pharmacologically, TDF is converted into its metabolite, tenofovir, prior to excretion of
tenofovir into breast milk, and tenofovir is not absorbed by the adult gastrointestinal tract.62
Author Manuscript
Therefore, patients should be counseled regarding the scarcity of information on TDF and
breastfeeding, as well as the known benefits of breastfeeding, to make an informed
breastfeeding decision.
There are a few reports of lactic acidosis and hepatic steatosis in pregnant patients receiving
nucleos(t)ide analogues, so monitoring of liver enzymes and electrolytes is recommended.10
Postpartum flares of hepatitis may occur after stopping lamivudine in patients who receive it
during the last 4 weeks of pregnancy.31,34 For this reason, liver enzymes should be
monitored after delivery.
(EASL) address antiviral treatment in pregnancy for women with chronic HBV infection
(Table 4).58 It is suggested that women with mild liver disease and low HBV DNA levels
(chronic inactive HBV infection) complete pregnancy before antiviral treatment is
considered; that women with moderate liver disease and no cirrhosis (chronic active HBV
infection) undergo antiviral treatment and discontinue treatment before pregnancy if there is
a viral response; that women with advanced liver disease (cirrhosis) receive antiviral
treatment before, during and after pregnancy; and that women with mild liver disease and
very high HBV DNA levels (immune-tolerant chronic HBV infection) receive a category B
anti-viral agent (TDF or telbivudine) in the last trimester of pregnancy.58 The Asian Pacific
Association for the Study of the Liver (APASL) also recommends prophylactic antiviral
treatment in pregnant women with high levels of viremia.63
One of the most commonly cited American clinical guidelines for management of chronic
Author Manuscript
hepatitis B, authored and updated by Keefe et al.,20 states data from clinical studies indicate
that women with chronic hepatitis B who have HBV DNA levels>107 copies ml 1 and
elevated ALT levels, or who have had an HBsAg-positive child, are candidates for antiviral
therapy because of the increased risk for transmission to the newborn.
A recent publication proposed an algorithm for risk assessment and patient management
that is based on a review of the literature and the opinion of a panel of physicians with
expertise in preventing MTCT. The authors recommended that pregnant women with
Author Manuscript
chronic HBV infection who are at high risk for MTCT (because of HBV DNA levels >200
000 IU ml 1 or >6 log10 copies ml1, a previous child failed HBIG and HBV vaccine, or
who threaten abortion or premature delivery) receive antiviral treatment. The recommended
antiviral treatment is lamivudine or telbivudine, or TDF for those with chronic active
hepatitis B, beginning in the third trimester of pregnancy.31 (Figure 3)
789 patients.64 However, it was stated that the conclusions of this review must be
considered with great caution because of the high risk of bias in each included study (graded
C). Pan et al., 65 analyzed data from 1409 infants born through vaginal delivery, elective
cesarean section or urgent cesarean section to HBsAg-positive mothers who completed
appropriate immunization against HBV. HBV infection was transmitted to a smaller
percentage of infants born by elective cesarean section (1.4%) than by vaginal delivery
(3.4%, P<0.032) or urgent cesarean section (4.2%, P<0.020). Urgent cesarean section had
no effect on vertical transmission compared with vaginal delivery (P = 0.593), whereas
infants born by elective cesarean section had a significantly lower rate of vertical
transmission than those born by non-elective cesarean section (1.4 vs 36%, P = 0.17).
Women with HBV DNA levels<6 log10 copies ml1 did not transmit the infection to their
infants, regardless of the method of delivery, and there were no differences in maternal or
Author Manuscript
infant morbidity and mortality among the groups. The authors conclude that elective
cesarean sections for HBeAg-positive mothers with levels of HBV DNA 6 log10 copies
ml1 could reduce vertical HBV transmission.
vaccination testing of the infant for HBsAg and HBsAb should be performed after
Author Manuscript
HEPATITIS C IN PREGNANCY
Chronic HCV infection is a major public health problem in the US, accounting for most
cases of viral hepatitis in adults and affecting 1 to 2% of the population.69 Most young
women with chronic hepatitis C have no signs or symptoms of liver disease. The prevalence
of HCV infection among women of childbearing age in the US is approximately 1%.70
Prevalence is increased among pregnant women with specific risk factors: intravenous drug
use, inhaled drug use, transfusions prior to 1992, homemade tattoos, and HIV infection. The
prevalence of HCV infection in pregnant women with intravenous drug use reaches 70 to
Author Manuscript
95%.71
We recommend that all pregnant women with risk factors for hepatitis C, or with abnormal
Author Manuscript
transaminase levels, undergo screening for antibody to HCV. Polymerase chain reaction
(PCR) for detection and quantitation of HCV RNA should be performed if HCV antibody is
positive.7 Only 60 to 70% of young women who are HCV antibody-positive will have active
infection with detectable HCV RNA by PCR;75 30 to 40% of young women exposed to
HCV will spontaneously clear the virus and have no chronic HCV infection. Women who
are PCR-positive for HCV RNA are at risk for MTCT, and infants born to these mothers
should be screened for HCV infection.
of those with an elevated ALT level decreased from 56% at the beginning of pregnancy to
7% by the third trimester.76 However, a rise in HCV RNA levels may be noted during the
third trimester.77 The improvement of serum ALT levels despite an increase in HCV RNA
levels may be due to a pregnancy-related decrease in the immune response to HCV.78
(10/108). These data are consistent with the reported increased prevalence of cholestasis of
pregnancy in Latino populations.79 Two other studies have demonstrated an association
between HCV infection and cholestasis of pregnancy; 15.9% of HCV antibody-positive
pregnant women developed cholestasis in one study,13 while the other found that cholestasis
developed in 20.3% of HCV RNA-positive pregnant women.14
Preterm birthLarge population studies indicate that chronic HCV infection is associated
with preterm birth.5,8 However, other factors may influence pregnancy outcomes in HCV
patients. Drug abuse, alcohol abuse and tobacco use were included in the multivariate
statistical analysis in the study by Connell.5 On the other hand, in the New Mexico study,
the incidence of preterm delivery, defined as delivery before 37 completed weeks of
gestation, was significantly increased in HCV antibody-positive pregnancies (24.5%
Author Manuscript
compared with 14.9%); however, when multivariate regression was used to adjust for
methadone use, tobacco use and prior preterm delivery, there was no significant difference.7
perinatal HCV transmission include higher levels of HCV viremia HIV-HCV co-infection,
prolonged rupture of membranes and invasive fetal monitoring (Table 6).
recent study found that an HCV RNA level over 600 000 IU ml1 was associated with an
Author Manuscript
Though the rate of MTCT of HCV infection is not effected by HCV genotype, the rate of
HCV chronicity may be higher for infants with HCV genotype 1 than for those with other
genotypes, because of less frequent spontaneous viral clearance.82,83 Recent studies also
indicate that there is a relationship between the interleukin 28B (IL28B) genotype and
spontaneous clearance of HCV.84 The IL28B genotype of mother and child does not
influence MTCT of HCV infection; however, 83% of infants with the CC genotype
exhibited spontaneous HCV clearance vs only 22% of the children with a non-CC
genotype.82
study91 suggest that cesarean section does not decrease perinatal HCV transmission from
HCV RNA-positive, HIV-negative mothers to infants. There are no randomized controlled
trials of cesarean section vs vaginal delivery for preventing MTCT of HCV infection.
similar rates of infection are observed in breastfed and bottle-fed infants, or no viral
Author Manuscript
For patients who are not pregnant, antiviral therapy for HCV has become less toxic and
more efficacious. Until recently, recommendations for HCV treatment were pegylated
Author Manuscript
interferon plus ribavirin for genotype 2 or 3 HCV infection, and a three-drug regimen
(pegylated interferon injection with oral ribavirin plus a protease inhibitor such as
boceprevir or telaprevir) for genotype 1 HCV infection. However, the Food and Drug
Administration has recently approved a new once/day protease inhibitor, simeprevir, as well
as sofosbuvir, an oral HCV polymerase inhibitor. These interferon-free regimens have been
in use since January 2014, but have not been studied for use during pregnancy.100104 The
question of HCV treatment with these new medications during pregnancy, now not
recommended, will surface. Treatment of HCV-infected pregnant women might be
envisioned in the future if non-teratogenic regimens are developed, which could further
reduce the up to 10% risk of MTCT and the long-term health burden of HCV infection
resulting from vertical transmission.
Author Manuscript
completed breastfeeding.
copies ml1) to decrease the rate of MTCT of HBV infection (Level A) (Table 7). All infants
Author Manuscript
born to HBsAg-positive mothers should receive HBIG and HBV vaccine as early as
possible, no later than 12 h after birth (Level A). Newborns of mothers with unknown
hepatitis B status should also receive immunoprophylaxis (Level C). The vaccine series
should be completed according to recommended schedules.107 Current guidelines do not
recommend elective cesarean delivery for mothers with chronic HBV infection (Level B);
however, a recent nonrandomized study showed elective cesarean section may decrease
vertical transmission of HBV if the HBV DNA level is >20 million IU ml 1 (> 6 log10
copies ml1) at term. 65 Breast feeding does not increase MTCT of HBV and is not
contraindicated (Level B), though breast feeding is not recommended during maternal
antiviral therapy by drug manufacturers (Level C).
We recommend that all pregnant women with risk factors for hepatitis C or with abnormal
ALT levels undergo screening for antibodies to HCV; if positive, PCR for quantitation of
Author Manuscript
HCV RNA level should be performed (Level B). Women who are PCR-positive for HCV are
at risk for MTCT of HCV, and infants born to these mothers should be screened for HCV
infection (Level B). Women with HCV infection are at an increased risk for cholestasis of
pregnancy (Level B). HCV-infected women on methadone have an increased risk for
preterm birth, while their infants have a high incidence of neonatal withdrawal syndrome
(Level C). Unlike HBV, patients are typically not treated for HCV during pregnancy.
However, young women are ideal candidates for treatment of HCV infection in the
postpartum period, with a greater than 90% chance of resolving the infection with less toxic
and more efficacious new regimens (Level A).
Acknowledgments
Author Manuscript
This work was partially supported the Department of Obstetrics and Gynecology Research Development and
Faculty Development Funds at the University of Iowa.
References
1. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National Institutes of
Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern
Med. 2009; 150(2):104110. [PubMed: 19124811]
2. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection:
New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12):2212
2219. [PubMed: 22273662]
3. Merrill RM, Hunter BD. Seroprevalence of markers for hepatitis B viral infection. Int J Infect Dis.
2011; 15(2):E78E121. [PubMed: 21130675]
4. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007;
42(7):513521. [PubMed: 17653645]
Author Manuscript
5. Connell LE, Salihu HM, Salemi JL, August EM, Weldeselasse H, Mbah AK. Maternal hepatitis B
and hepatitis C carrier status and perinatal outcomes. Liver Int. 2011; 31(8):11631170. [PubMed:
21745298]
6. Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. Pregnancy outcomes associated with
viral hepatitis. J Viral Hepat. 2011; 18(7):e394e398. [PubMed: 21692952]
7. Berkley EM, Leslie KK, Arora S, Qualls C, Dunkelberg JC. Chronic hepatitis C in pregnancy.
Obstet Gynecol. 2008; 112(2 Pt 1):304310. [PubMed: 18669727]
8. Safir A, Levy A, Sikuler E, Sheiner E. Maternal hepatitis B virus or hepatitis C virus carrier status
as an independent risk factor for adverse perinatal outcome. Liver Int. 2010; 30(5):765770.
Author Manuscript
[PubMed: 20214739]
9. Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a
case-control study. J Hepatol. 2005; 43(5):771775. [PubMed: 16139923]
10. Gambarin-Gelwan M. Hepatitis B in pregnancy. Clin Liver Dis. 2007; 11(4):945963. x. [PubMed:
17981236]
11. Lao TT, Chan BC, Leung WC, Ho LF, Tse KY. Maternal hepatitis B infection and gestational
diabetes mellitus. J Hepatol. 2007; 47(1):4650. [PubMed: 17434231]
12. Pergam SA, Wang CC, Gardella CM, Sandison TG, Phipps WT, Hawes SE. Pregnancy
complications associated with hepatitis C: data from a 20032005 Washington state birth cohort.
Am J Obstet Gynecol. 2008; 199(1):38, e31e39. [PubMed: 18486089]
13. Locatelli A, Roncaglia N, Arreghini A, Bellini P, Vergani P, Ghidini A. Hepatitis C virus infection
is associated with a higher incidence of cholestasis of pregnancy. Br J Obstet Gynaecol. 1999;
106(5):498500. [PubMed: 10430202]
14. Paternoster DM, Fabris F, Palu G, Santarossa C, Bracciante R, Snijders D, et al. Intra-hepatic
Author Manuscript
cholestasis of pregnancy in hepatitis C virus infection. Acta Obstet Gynecol Scand. 2002; 81(2):
99103. [PubMed: 11942897]
15. Ludlow JP, Evans SF, Hulse G. Obstetric and perinatal outcomes in pregnancies associated with
illicit substance abuse. Aust N Z J Obstet Gynaecol. 2004; 44(4):302306. [PubMed: 15282000]
16. Euler GL, Wooten KG, Baughman AL, Williams WW. Hepatitis B surface antigen prevalence
among pregnant women in urban areas: implications for testing, reporting, and preventing
perinatal transmission. Pediatrics. 2003; 111(5 Part 2):11921197. [PubMed: 12728137]
17. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of
hepatitis B surface antigen. Am J Epidemiol. 1977; 105(2):9498. [PubMed: 835566]
18. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. e antigen and anti-e in the serum of
asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B
virus to their infants. N Engl J Med. 1976; 294(14):746749. [PubMed: 943694]
19. Stevens CE, Neurath RA, Beasley RP, Szmuness W. HBeAg and anti-HBe detection by
radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med
Author Manuscript
25. Ornoy A, Tenenbaum A. Pregnancy outcome following infections by coxsackie, echo, measles,
mumps, hepatitis, polio and encephalitis viruses. Reprod Toxicol. 2006; 21(4):446457. [PubMed:
16480851]
26. Rawal BK, Parida S, Watkins RP, Ghosh P, Smith H. Symptomatic reactivation of hepatitis B in
pregnancy. Lancet. 1991; 337(8737):364. [PubMed: 1671257]
27. Lin HH, Chen PJ, Chen DS, Sung JL, Yang KH, Young YC, et al. Postpartum subsidence of
hepatitis B viral replication in HBeAg-positive carrier mothers. J Med Virol. 1989; 29(1):16.
[PubMed: 2584955]
28. Lin HH, Wu WY, Kao JH, Chen DS. Hepatitis B post-partum e antigen clearance in hepatitis B
carrier mothers: Correlation with viral characteristics. J Gastroenterol Hepatol. 2006; 21(3):605
Author Manuscript
34. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to
prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-
blind, placebo-controlled study. J Viral Hepat. 2009; 16(2):94103. [PubMed: 19175878]
35. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-
active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012;
19(2):e18e25. [PubMed: 22239517]
36. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol. 2003; 39(Suppl
1):S64S69. [PubMed: 14708680]
37. Wang JS, Chen H, Zhu QR. Transformation of hepatitis B serologic markers in babies born to
hepatitis B surface antigen positive mothers. World J Gastroenterol. 2005; 11(23):35823585.
[PubMed: 15962380]
38. Xu ZY, Duan SC, Margolis HS, Purcell RH, Ou-Yang PY, Coleman PJ, et al. Long-term efficacy
of active postexposure immunization of infants for prevention of hepatitis B virus infection.
United States-Peoples Republic of China Study Group on Hepatitis B. J Infect Dis. 1995; 171(1):
5460. [PubMed: 7798683]
Author Manuscript
39. Krugman S. Hepatitis B virus and the neonate. Ann NY Acad Sci. 1988; 549:129134. [PubMed:
3228250]
40. Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, et al. Efficacy of hepatitis B
immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final
report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983; 3(2):135141.
[PubMed: 6339349]
41. Schalm SW, Mazel JA, de Gast GC, Heijtink RA, Botman MJ, Banffer JR, et al. Prevention of
hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of
mothers with hepatitis B surface antigen. Pediatrics. 1989; 83(6):10411048. [PubMed: 2726331]
42. Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV, et al. Perinatal hepatitis B virus
transmission in the United States. Prevention by passive-active immunization. JAMA. 1985;
253(12):17401745. [PubMed: 3974052]
43. Lin HH, Lee TY, Chen DS, Sung JL, Ohto H, Etoh T, et al. Transplacental leakage of HBeAg-
positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B
Author Manuscript
47. Andre FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. J Med
Virol. 1994; 44(2):144151. [PubMed: 7852954]
Author Manuscript
48. Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN, Nair PV, et al. Yeast-recombinant hepatitis B
vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus
transmission. JAMA. 1987; 257(19):26122616. [PubMed: 2952812]
49. Noto H, Terao T, Ryou S, Hirose Y, Yoshida T, Ookubo H, et al. Combined passive and active
immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus carrier state in
Shizuoka, Japan during 19801994. J Gastroenterol Hepatol. 2003; 18(8):943949. [PubMed:
12859724]
50. Soleimani Amiri MJ, Hasanjani Roushan MR, Baiany M, Taheri H, Hasanjani Roushan M.
Outcomes of passive-active immunoprophylaxis given to infants of mothers infected with hepatitis
B virus in Babol, Iran. J Clin Virol. 2010; 49(4):283285. [PubMed: 20846904]
51. Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state
in infants according to maternal serum levels of HBV DNA. Lancet. 1989; 1(8635):406410.
[PubMed: 2563788]
52. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine
Author Manuscript
for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998; 339(2):61
68. [PubMed: 9654535]
53. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, et al. A prospective and open-label
study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal
transmission of hepatitis B virus infection. J Hepatol. 2011; 55(6):12151221. [PubMed:
21703206]
54. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero
transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010;
116(1):147159. [PubMed: 20567182]
55. Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y. Efficacy and safety of lamivudine
treatment for chronic hepatitis B in pregnancy. World J Gastroenterol. 2004; 10(6):910912.
[PubMed: 15040044]
56. Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW. A meta-analysis of lamivudine for
interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol. 2011;
17(38):43214333. [PubMed: 22090789]
Author Manuscript
57. Peters MG. Special populations with hepatitis B virus infection. Hepatology. 2009; 49(5
Suppl):S146S155. [PubMed: 19399810]
58. European Association For The Study Of The Liver. EASL clinical practice guidelines:
Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1):167185. [PubMed:
22436845]
59. Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, et al. Telbivudine prevents vertical
transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol.
2012; 10(5):520526. [PubMed: 22343511]
60. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009; 49(5
Suppl):S185S195. [PubMed: 19399802]
61. Benaboud S, Pruvost A, Coffie PA, Ekouevi DK, Urien S, Arrive E, et al. Concentrations of
tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote dIvoire, in
the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother. 2011; 55(3):13151317.
[PubMed: 21173182]
Author Manuscript
62. Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G, et al. Tenofovir disoproxil
fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic
pregnant women: a case series. Dig Dis Sci. 2012; 57(9):24232429. [PubMed: 22543886]
63. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus
statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6(3):531
561. [PubMed: 26201469]
64. Yang J, Zeng XM, Men YL, Zhao LS. Elective caesarean section versus vaginal delivery for
preventing mother to child transmission of hepatitis B virus--a systematic review. Virol J. 2008;
5:100. [PubMed: 18755018]
65. Pan CQ, Zou HB, Chen Y, Zhang XH, Zhang H, Li J, et al. Cesarean section reduces perinatal
transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their
Author Manuscript
and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol.
2000; 32(2):293299. [PubMed: 10707870]
78. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the
maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today. 1993;
14(7):353356. [PubMed: 8363725]
79. Lee RH, Goodwin TM, Greenspoon J, Incerpi M. The prevalence of intrahepatic cholestasis of
pregnancy in a primarily Latina Los Angeles population. J Perinatol. 2006; 26(9):527532.
[PubMed: 16761011]
80. Ohto H, Terazawa S, Sasaki N, Hino K, Ishiwata C, Kako M, et al. Transmission of hepatitis C
virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study
Group. N Engl J Med. 1994; 330(11):744750. [PubMed: 8107740]
81. Ferrero S, Lungaro P, Bruzzone BM, Gotta C, Bentivoglio G, Ragni N. Prospective study of
mother-to-infant transmission of hepatitis C virus: a 10-year survey (19902000). Acta Obstet
Gynecol Scand. 2003; 82(3):229234. [PubMed: 12694118]
82. Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA, de Rueda PM, Quiles-Perez R, Gila-
Author Manuscript
Medina A, et al. Genetic variation in interleukin 28B with respect to vertical transmission of
hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology. 2011; 53(6):
18301838. [PubMed: 21413051]
83. Bortolotti F, Verucchi G, Camma C, Cabibbo G, Zancan L, Indolfi G, et al. Long-term course of
chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology.
2008; 134(7):19001907. [PubMed: 18439604]
84. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, OHuigin C, et al. Genetic variation in IL28B and
spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265):798801. [PubMed:
19759533]
85. Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH, et al. Perinatal
transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers.
Author Manuscript
Women and Infants Transmission Study. J Infect Dis. 1998; 177(6):14801488. [PubMed:
9607823]
86. Thaler MM, Park CK, Landers DV, Wara DW, Houghton M, Veereman-Wauters G, et al. Vertical
transmission of hepatitis C virus. Lancet. 1991; 338(8758):1718. [PubMed: 1676085]
87. Zanetti AR, Tanzi E, Paccagnini S, Principi N, Pizzocolo G, Caccamo ML, et al. Mother-to-infant
transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet.
1995; 345(8945):289291. [PubMed: 7530793]
88. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal
transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in
infancy. J Infect Dis. 2005; 192(11):18801889. [PubMed: 16267758]
89. Steininger C, Kundi M, Jatzko G, Kiss H, Lischka A, Holzmann H. Increased risk of mother-to-
infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J
Infect Dis. 2003; 187(3):345351. [PubMed: 12552417]
90. Centers for Disease Control and Prevention. Recommendations for prevention and control of
Author Manuscript
hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;
47(RR-19):139.
91. European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on
the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus
Network. BJOG. 2001; 108(4):371377. [PubMed: 11305543]
92. McIntyre PG, Tosh K, McGuire W. Caesarean section versus vaginal delivery for preventing
mother to infant hepatitis C virus transmission. Cochrane Database Syst Rev. 2006;
(4):CD005546. [PubMed: 17054264]
93. Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M, et al. Mother-to-child
transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet. 2000;
356(9233):904907. [PubMed: 11036896]
94. Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, Alavian SM. Effect of cesarean section on
the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV- mothers: a meta-
analysis. Arch Gynecol Obstet. 2011; 283(2):255260. [PubMed: 20652289]
95. Polywka S, Schroter M, Feucht HH, Zollner B, Laufs R. Low risk of vertical transmission of
Author Manuscript
hepatitis C virus by breast milk. Clin Infect Dis. 1999; 29(5):13271329. [PubMed: 10524987]
96. Kumar RM, Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of
HCV-infected mothers. J Hepatol. 1998; 29(2):191197. [PubMed: 9722199]
97. Resti M, Azzari C, Mannelli F, Moriondo M, Novembre E, de Martino M, et al. Mother to child
transmission of hepatitis C virus: prospective study of risk factors and timing of infection in
children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus
Infection. BMJ. 1998; 317(7156):437441. [PubMed: 9703524]
98. Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. A review of hepatitis C virus (HCV)
vertical transmission: risks of transmission to infants born to mothers with and without HCV
viraemia or human immunodeficiency virus infection. Int J Epidemiol. 1998; 27(1):108117.
[PubMed: 9563703]
99. American College of Obstetricians and Gynecologists. ACOG committee opinion. Breastfeeding
and the risk of hepatitis C virus transmission. Number 220, August 1999. Committee on Obstetric
Practice. Int J Gynaecol Obstet. 1999; 66(3):307308. [PubMed: 10580686]
Author Manuscript
100. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir
for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368(20):18781887.
[PubMed: 23607594]
101. Jesudian AB, de Jong YP, Jacobson IM. Emerging therapeutic targets for hepatitis C virus
infection. Clin Gastroenterol Hepatol. 2013; 11(6):612619. e611. [PubMed: 23583900]
102. Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Direct-acting
antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol. 2013; 12(5):
728737. [PubMed: 23872239]
103. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al.
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J
Author Manuscript
Figure 1.
Phases of chronic HBV infection. In the immune-tolerant phase of chronic HBV infection,
ALT levels are normal whereas HBV DNA levels are markedly elevated. In the immune-
reactive or chronic active phases, ALT and HBV DNA levels are elevated. In chonic
inactive phases of HBV infection, ALT and HBV DNA levels are decreased; <1000 IU ml1
is equivalent to <6 3 log10 copies ml1; >200 000 IU ml1 is>6 log10 copies ml1.
Author Manuscript
Author Manuscript
Figure 2.
HBsAg is checked in all pregnant women. HBsAg-positive patients should have HBV DNA
level and HBeAg checked. We recommend checking HBsAb and immunizing HBsAb-
negative patients.
Author Manuscript
Author Manuscript
Figure 3.
Pregnant women with HBV DNA levels >200 000 IU ml1 (>6 log10 copies ml1), or any
HBsAg-positive woman with a threatened abortion, are at high risk for MTCT and should
receive antiviral treatment in the third trimester.31
Author Manuscript
Author Manuscript
Table 1
Table 2
Diagnosis of hepatitis B
Author Manuscript
Table 3
Immunoprophylaxis of neonates with HBIG+HBV vaccine is superior to monotherapy with either agent alone
Author Manuscript
Abbreviations: HBIG, hepatitis B immune globulin; HBV, hepatitis B virus; MTCT, mother-to-child transmission. References: 23, 47.
a
A major risk for immunoprophylaxis failure is maternal HBV DNA level >200 000 IU ml1 (>6 log10 copies ml1).
Author Manuscript
Author Manuscript
Author Manuscript
Table 4
European Association for Study of the Liver (EASL) recommendation for antiviral therapy for HBV-infected
Author Manuscript
Mild liver disease, low viremia (chronic inactive HBV) Pregnancy before treatment
Moderate liver disease, no cirrhosis (chronic active HBV) Treatment before pregnancy; if responds, stop treatment before pregnancy
Advanced liver disease (advanced fibrosis-cirrhosis) Treatment before, during and after pregnancy
Mild liver disease, very high viremia (immunotolerant) Treatment in last trimester with a B category drug with post-partum
discontinuation
Table 5
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; HBV, hepatitis B virus, HCV, hepatitis C virus.
Author Manuscript
Author Manuscript
Author Manuscript
Table 6
MTCT of HCV
Author Manuscript
Table 7